Education ▼

SPECIALTY TOPICS

CURRENTLY VIEWING
Gynecologic Oncology

Breast Cancer

Multiple Myeloma

Lung Cancer

Immuno-Oncology News

Gastrointestinal Cancer

Gynecologic Oncology

ESMO 2018: Olaparib Substantially Improves PFS as Frontline Maintenance in Ovarian Cancer

The PARP inhibitor olaparib significantly improved progression-free survival as frontline maintenance therapy for women with BRCA-positive advanced ovarian cancer, according to findings from the randomized phase III SOLO-1 trial.
Read More >>

ESMO 2018: Engineered Anti-MAGE-A T-Cells Show Early Promise

ESMO 2018: Niraparib Effective in Later Lines of Therapy for Relapsed Ovarian Cancer

NCCN Issues Guidelines for Management of Rare Gestational Cancers

New Law Widens Access to Genetic Counseling but Licensure and Coverage Barriers Persist

FDA Approves Gardasil 9 HPV Vaccine for Use Up to Age 45

View More Stories >>

View Conference Coverage

2018 State of the Science Summit on Hematologic Malignancies in Clayton

State of the Science Summit on GI Cancers in Newport Beach

2018 ESMO Congress

2018 State of the Science Summit on Hematologic Malignancies in Cleveland

2018 Lynn Sage Breast Cancer Symposium

Dr. Powell on Tumor Mutational Burden in Ovarian Cancer

Dr. Campos on Next Steps With PARP Inhibitors in Ovarian Cancer

Dr. Ginsburg Discusses the Use of VIA in Cervical Cancer Screening

Dr. Herzog on the Use of HIPEC in Ovarian Cancer

Dr. Powell on the Future of Immunotherapy in Ovarian Cancer

Dr. Tewari on the Trial Design With Cemiplimab in Cervical Cancer

OncLive houses thousands of videos that provide updates and information.
See more Videos

Improvements in Advanced Ovarian Cancer

Novel Treatment Strategies in Recurrent Ovarian Cancer

PARP Combination Therapies in Ovarian Cancer

Ongoing PARP Trials in Recurrent Ovarian Cancer

Recurrent Ovarian Cancer: PARP Inhibitors Compared

Using Maintenance Therapy in Recurrent Ovarian Cancer

PARP Maintenance Therapy in Recurrent Ovarian Cancer

OncLive houses thousands of videos that provide updates and information.
See more Videos

The Future Role of PARP Inhibition in Ovarian Cancer

Combinations With PARP Inhibitors for Ovarian Cancer

Ovarian Cancer: Selecting an Appropriate PARP Inhibitor

Ovarian Cancer: Treating Through Multiple Progressions

Ovarian Cancer: Comparisons Between PARP Inhibitors

Ovarian Cancer: Deciding Among PARP Inhibitors

Ovarian Cancer: Optimizing Treatment With Niraparib

OncLive houses thousands of videos that provide updates and information.
See more Videos

Featured Programs

Emerging Concepts-Advanced Ovarian, Fallopian, Peritoneal, and Cervical Cancers

This discussion, led by James Tate Thigpen, MD, features the most recent information pertaining to treatment of gynecologic malignancies. The expert panel, Robert L. Coleman, MD, FACOG, FACS; Thomas Herzog, MD; Bradley J. Monk, MD, FACOG, FACS; and Angeles Alvarez Secord, MD, review the research and how to apply it in practice.View Now

Challenges for the Future of Gynecologic Cancers

Panelists provide their perspectives on the key challenges facing the future of ovarian and cervical cancer treatment.View Now

Featured Video

Immunotherapy in the Treatment of Follicular Lymphoma

Ian W. Flinn, MD, PhD; Grzegorz S. Nowakowski, MD; Loretta J. Nastoupil, MD; and Anas Younes, MD, reflect on the value of immunotherapy, immunotherapy combination strategies, and understanding the tumor microenvironment in treating follicular lymphoma.View now

OncLive News Network On Location: 2018 ESMO Congress